Intravitreal Delivery of A190 loaded Microparticles in a Model of Age-related Macular Degeneration
Tuesday, July 15, 2025
3:16 PM – 3:27 PM EDT
Introduction: Age-related macular degeneration (AMD) is a major global health challenge, causing vision impairment and compromised quality of life in the elderly population [1,2]. Therapeutic potential of peroxisome proliferator-activated receptor α (PPARα) agonists in retinal diseases is well-documented [3,4]. A190, a novel non-fibrate PPARα agonist, exhibits superior potency and selectivity for PPARα receptors [5]. This study aimed to assess the ocular pharmacokinetics of A190-MP and evaluate its efficacy in a murine model of dry AMD over a six-month period following a single intravitreal injection.
Learning Objectives:
At the completion of this activity, participants will know
Understand the role and therapeutic potential of PPARα agonists in treatment of retinal diseases.
Importance of sustained drug delivery strategies for the management of retinal diseases.
